+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epilepsy Therapeutic Market in APAC 2021-2025

  • ID: 5143022
  • Report
  • April 2021
  • Region: Asia Pacific
  • 120 Pages
  • TechNavio
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • BIAL - PORTELA & CA SA
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • SanofiSA
  • UCB SA
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the epilepsy therapeutic market in APAC and it is poised to grow by $ 296.44 mn during 2021-2025, progressing at a CAGR of about 4% during the forecast period. The report on epilepsy therapeutic market in APAC provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current APAC market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high unmet medical need, increase in patient population, and rising awareness.

The epilepsy therapeutic market in APAC analysis includes product segment and geographic landscape.

The epilepsy therapeutic market in APAC is segmented as below:

By Product
  • First-generation epilepsy therapeutics
  • Second-generation epilepsy therapeutics
  • Third-generation epilepsy therapeutics

By Geographical Landscape
  • Asia
  • Rest of APAC

This study identifies the reformulation of marketed drugs as one of the prime reasons driving the epilepsy therapeutic market in APAC growth during the next few years. Also, the emergence of new-generation AEDS, and AEDS with novel mechanisms of action will lead to sizable demand in the market.

The report on epilepsy therapeutic market in APAC covers the following areas:
  • Epilepsy therapeutic market in APAC sizing
  • Epilepsy therapeutic market in APAC forecast
  • Epilepsy therapeutic market in APAC industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epilepsy therapeutic market in APAC vendors that include Bausch Health Companies Inc., BIAL - PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., SanofiSA, Sunovion Pharmaceuticals Inc., UCB SA, and Zogenix Inc. Also, the epilepsy therapeutic market in APAC analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • BIAL - PORTELA & CA SA
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • SanofiSA
  • UCB SA

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product
  • Market segments
  • Comparison by Product
  • First-generation epilepsy therapeutics - Market size and forecast 2020-2025
  • Second-generation epilepsy therapeutics - Market size and forecast 2020-2025
  • Third-generation epilepsy therapeutics - Market size and forecast 2020-2025
  • Market opportunity by Product

Customer landscape
  • Overview

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • Asia - Market size and forecast 2020-2025
  • Rest of APAC - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Bausch Health Companies Inc.
  • BIAL - PORTELA & CA SA
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • SanofiSA
  • Sunovion Pharmaceuticals Inc.
  • UCB SA
  • Zogenix Inc.

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Product - Market share 2020-2025 (%)
  • Comparison by Product
  • First-generation epilepsy therapeutics - Market size and forecast 2020-2025 ($ million)
  • First-generation epilepsy therapeutics - Year-over-year growth 2020-2025 (%)
  • Second-generation epilepsy therapeutics - Market size and forecast 2020-2025 ($ million)
  • Second-generation epilepsy therapeutics - Year-over-year growth 2020-2025 (%)
  • Third-generation epilepsy therapeutics - Market size and forecast 2020-2025 ($ million)
  • Third-generation epilepsy therapeutics - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Product
  • Customer landscape
  • Market share by geography 2020-2025 (%)
  • Geographic comparison
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • Rest of APAC - Market size and forecast 2020-2025 ($ million)
  • Rest of APAC - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • Bausch Health Companies Inc. - Overview
  • Bausch Health Companies Inc. - Business segments
  • Bausch Health Companies Inc. - Key offerings
  • Bausch Health Companies Inc. - Key customers
  • Bausch Health Companies Inc. - Segment focus
  • BIAL - PORTELA & CA SA - Overview
  • BIAL - PORTELA & CA SA - Product and service
  • BIAL - PORTELA & CA SA - Key offerings
  • BIAL - PORTELA & CA SA - Key customers
  • BIAL - PORTELA & CA SA - Segment focus
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Key customers
  • GlaxoSmithKline Plc - Segment focus
  • Johnson & Johnson Services, Inc. - Overview
  • Johnson & Johnson Services, Inc. - Product and service
  • Johnson & Johnson Services, Inc. - Key offerings
  • Johnson & Johnson Services, Inc. - Key customers
  • Johnson & Johnson Services, Inc. - Segment focus
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key offerings
  • Novartis AG - Key customers
  • Novartis AG - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • SanofiSA - Overview
  • SanofiSA - Business segments
  • SanofiSA - Key offerings
  • SanofiSA - Key customers
  • SanofiSA - Segment focus
  • Sunovion Pharmaceuticals Inc. - Overview
  • Sunovion Pharmaceuticals Inc. - Product and service
  • Sunovion Pharmaceuticals Inc. - Key offerings
  • Sunovion Pharmaceuticals Inc. - Key customers
  • Sunovion Pharmaceuticals Inc. - Segment focus
  • UCB SA - Overview
  • UCB SA - Product and service
  • UCB SA - Key offerings
  • UCB SA - Key customers
  • UCB SA - Segment focus
  • Zogenix Inc. - Overview
  • Zogenix Inc. - Product and service
  • Zogenix Inc. - Key offerings
  • Zogenix Inc. - Key customers
  • Zogenix Inc. - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • BIAL - PORTELA & CA SA
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • SanofiSA
  • UCB SA
The publisher recognizes the following companies as the key players in the epilepsy therapeutic market in APAC: Bausch Health Companies Inc., BIAL - PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., SanofiSA, Sunovion Pharmaceuticals Inc., UCB SA, and Zogenix Inc.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the reformulation of marketed drugs.'

According to the report, one of the major drivers for this market is the high unmet medical need.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Bausch Health Companies Inc.
  • BIAL - PORTELA & CA SA
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
  • SanofiSA
  • Sunovion Pharmaceuticals Inc.
  • UCB SA
  • Zogenix Inc.
Note: Product cover images may vary from those shown